This is a phase II study using risk and response-adapted therapy for low, intermediate and
high risk classical Hodgkin lymphoma. Chemotherapy regimens will be based on risk group
assignment. Low-risk and intermediate- risk patients will be treated with bendamustine,
etoposide, Adriamycin® (doxorubicin), bleomycin, Oncovin® (vincristine), vinblastine, and
prednisone (BEABOVP) chemotherapy. High-risk patients will receive Adcetris® (brentuximab
vedotin), etoposide, prednisone and Adriamycin® (doxorubicin) (AEPA) and cyclophosphamide,
Adcetris® (brentuximab vedotin), prednisone and Dacarbazine® (DTIC) (CAPDac) chemotherapy.
Residual node radiotherapy will be given at the end of all chemotherapy only to involved
nodes that do not have an adequate response (AR) after 2 cycles of therapy for all risk
groups.
Phase:
Phase 2
Details
Lead Sponsor:
St. Jude Children's Research Hospital
Collaborators:
Seagen Inc. Seattle Genetics, Inc. Teva Pharmaceuticals USA